Abstract
Advances over the past 50years in the field of vaccination and the exploration of the immune response offer positive prospects for the prevention of infectious diseases. However, there is still a long way to go to improve the efficacy and safety of vaccination for transplant recipients or immunocompromised patients in the broad sense. In these populations, the benefit/risk balance of vaccination is even more pronounced in favor than that of the general population. Thus, consistently generating data in these populations is of great importance but can be disrupted by various human, technical and financial factors. In this text, we will attempt to describe some of these limitations for the immune response to vaccination and its exploration, especially in transplant recipients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
